Cambridge Healthtech Institute’s 11th Annual

Optimizing Cell Line Development

Enhancing Expression

August  15-16 , 2019


Cell Line Development has reached a new plateau influenced by genomic research and insights, along with emerging technologies that are pushing cell engineering into an uncharted future. The “Optimizing Cell Line Development” conference brings together experts who are forging this new era. They will share how to best optimize codons, construct vectors, and how to select and engineer clones and host systems, while maintaining stability and consistency. The conference will also focus on genomic research for CHO and other systems, as well as glycoengineering, systems biology, assays, and pathway delineation.  In addition, challenges for introducing new technologies will be discussed, along with an overview of industrial trends and regulatory perspectives.

Preliminary Agenda

KEYNOTE SESSION

KEYNOTE PRESENTATION:
A Novel Mammalian Cell Line Development Platform utilizing Nanofluidics and Optoelectro Positioning Technology

Jennitte Stevens, PhD, Director and Group Leader, Biologics Optmization, Amgen, Inc.

 

KEYNOTE PRESENTATION:
Mammalian Synthetic Biology: Foundations and Application to Cell Line Engineering

Ron Weiss, PhD, Professor, Biological Engineering, Massachusetts Institute of Technology (MIT)

DEVELOPING CHO-BASED CELL LINES

FEATURED PRESENTATION:
Regulating Recombinant Protein Expression during CHO Pool Selection Increases Productivity

Yves Durocher, PhD, Section Head, Mammalian Cell Expression, National Research Council Canada

 

The Development of Advanced Synthetic Biology Tools to Accelerate CHO Cell Line Engineering

Jicong Cao, PhD, Postdoctoral Associate, Massachusetts Institute of Technology (MIT)

 

Challenges on Stable Cell Line Development using Horizon CHO GS Knock Out System

Qinghua Jenny Zhao, MSc, Associate Director, Process Development & Operation, Salubris Biotherapeutics

INNOVATING CELL LINE SELECTION

Replacing an Early-Stage Cell Line with a Higher Producing Cell Line – A Case Study

Marieke (Koedood) Zhao, Associate Director, Cell Line Development, Mersana Therapeutics

 

Using siRNA for Cell Line Selection

Edward Eveleth, MS, CEO, HocusLocus, Inc.

 

ENGINEERING IMPROVED PROPERTIES

An Artificial Golgi Reactor as an Alternative Method for Targeted Cell-Free Glycosylation

Elli Makrydaki, MS, Graduate Research and Teaching Assistant, Chemical Engineering, Imperial College London

 

Platform Approaches Enabling Single-Cycle Cell Line Development

Linda Francullo, Principal Scientist, Drug Substance Development, Pfizer, Inc.

 

Improved Single Cell Cloning Method for High Clonality Assurance

Ren Liu, PhD, Associate Principal Scientist, Merck & Co., Inc.

 


* The program is subject to change without notice, due to unforeseen reason.